Neurocrine biosciences reports fourth quarter and fiscal 2024 financial results and provides financial expectations for 2025

Ingrezza® (valbenazine) fourth quarter and full year 2024 net product sales of $615 million and $2.3 billion, representing year-over-year growth of 23% and 26% respectively ingrezza® (valbenazine) full year 2025 net product sales guidance of $2.5 - $2.6 billion crenessitytm (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia, approved and launched in the united states phase 3 programs for osavampator in major depressive disorder and nbi-'568 in schizophrenia initiating in the first half of 2025 san diego , feb. 6, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the fourth quarter and full year ended december 31, 2024 and provided financial guidance for 2025. "i'm proud of the tremendous progress we made last year with the continued growth of ingrezza for patients living with tardive dyskinesia or huntington disease chorea.
NBIX Ratings Summary
NBIX Quant Ranking